Institutional Review Board (IRB) Written Procedures | Shudarsana Company

FDA Issues New Guidance on IRB Written Procedures: Key Insights for Institutions

The U.S. Food and Drug Administration (FDA) has released updated guidance on Institutional Review Board (IRB) Written Procedures in February 2025 to align with evolving human subject research regulations. This new guidance reflects the FDA’s commitment to harmonizing regulations with the Department of Health and Human Services (HHS) and supporting the objectives of the 21st Century Cures Act.

Purpose of the Guidance

The guidance aims to help institutions and IRBs establish clear, comprehensive written procedures to enhance the protection of human subjects in clinical research. By providing a structured framework, the FDA seeks to ensure that research conducted under its jurisdiction meets consistent ethical and regulatory standards.

Key Highlights

✅ Checklist for Written Procedures

The FDA has introduced a Written Procedures Checklist to help IRBs create effective, organized, and transparent procedures. This checklist covers essential areas such as:

• Initial and continuing review of research
• Handling protocol changes
• Reporting adverse events and noncompliance
• Managing conflicts of interest
• Record-keeping and documentation

📌 Flexibility and Customization

Institutions have the flexibility to adapt the format and content of their written procedures to meet specific operational needs while maintaining compliance with FDA regulations.

📢 Enhanced Oversight and Reporting

The guidance emphasizes the importance of proper documentation and timely reporting to improve oversight and accountability in clinical research.

Why This Matters

This updated guidance reflects the FDA’s effort to enhance the efficiency and consistency of IRB operations, ensuring that human subject protections remain a top priority. Institutions that adopt the new checklist and guidelines will benefit from streamlined processes and improved compliance, ultimately fostering greater trust in clinical research outcomes.

👉 To access the full guidance document, visit: FDA IRB Written Procedures Guidance